
BioAge doses first patient in Phase 2 trial for BGE-102 targeting diabetic macular edema; data due 2027
BioAge Labs initiated dosing in its Phase 2 trial (QUELL-DME) for BGE-102, an oral NLRP3 inhibitor aimed at treating diabetic macular edema, with topline results expected in late 2027. The company also completed enrollment in a Phase 2 cardiovascular...





